Alldredge B, et al. - Researchers conducted an appraisal of the patient characteristics, safety, and efficacy measures of multiple sclerosis (MS) patients receiving rituximab (RTX), with the intention of determining the therapeutic benefit and safety of RTX in a real-world setting with long-term follow-up. At the end of the chart review period, clinical stability was reported in 87% subjects with relapsing remitting MS, 47% in those with primary progressive MS and 79% in individuals with neuromyelitis optica (NMO). Data disclosed that rituximab exhibited good tolerability and efficacy in cases of both relapsing and progressive forms of MS and NMO.